Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-1,003,074
Closed -$14.7M 3465
2025
Q3
$14.7M Sell
1,003,074
-60,898
-6% -$621K ﹤0.01% 1912
2025
Q2
$10.4M Buy
1,063,972
+78,201
+8% +$648K ﹤0.01% 1992
2025
Q1
$7.17M Buy
985,771
+174,945
+22% +$1.53M ﹤0.01% 2116
2024
Q4
$6.34M Buy
810,826
+89,776
+12% +$739K ﹤0.01% 2231
2024
Q3
$5.34M Buy
721,050
+53,932
+8% +$453K ﹤0.01% 2344
2024
Q2
$5.34M Buy
667,118
+37,885
+6% +$338K ﹤0.01% 2336
2024
Q1
$7.32M Buy
629,233
+129,880
+26% +$1.44M ﹤0.01% 2145
2023
Q4
$5.58M Buy
499,353
+10,349
+2% +$95.1K ﹤0.01% 2264
2023
Q3
$7.55M Buy
489,004
+322,339
+193% +$5.41M ﹤0.01% 2067
2023
Q2
$3.16M Buy
166,665
+145,639
+693% +$2.56M ﹤0.01% 2412
2023
Q1
$320K Buy
21,026
+5,724
+37% +$74.6K ﹤0.01% 3075
2022
Q4
$195K Hold
15,302
﹤0.01% 3190
2022
Q3
$89K Buy
+15,302
New +$67.2K ﹤0.01% 3233
2022
Q2
Sell
-20,663
Closed -$78K 3569
2022
Q1
$78K Sell
20,663
-4,146
-17% -$26.7K ﹤0.01% 3460
2021
Q4
$325K Hold
24,809
﹤0.01% 3269
2021
Q3
$487K Sell
24,809
-38,037
-61% -$695K ﹤0.01% 3156
2021
Q2
$1.18M Buy
62,846
+3,466
+6% +$77.4K ﹤0.01% 2870
2021
Q1
$1.41M Buy
59,380
+4,629
+8% +$107K ﹤0.01% 2746
2020
Q4
$1.33M Buy
54,751
+14,703
+37% +$376K ﹤0.01% 2697
2020
Q3
$1.03M Buy
40,048
+8,762
+28% +$278K ﹤0.01% 2668
2020
Q2
$624K Buy
31,286
+2,481
+9% +$60.3K ﹤0.01% 2754
2020
Q1
$728K Buy
28,805
+469
+2% +$13.7K ﹤0.01% 2575
2019
Q4
$745K Buy
+28,336
New +$789K ﹤0.01% 2686

Other funds holding ETNB

Charles Schwab's ETNB Position: Q4 2025 in Review

Charles Schwab sold out of 89bio (ETNB) in Q4 2025, closing a stake of 1,003,074 shares — an estimated $14.7M sold.

Charles Schwab first reported a position in ETNB in Q4 2019 and held it in 23 quarters. The position peaked at $14.7M in Q3 2025. 2 funds tracked by Wall St. Rank hold ETNB as of Q4 2025.

  • Charles Schwab reported no remaining 89bio position as of Q4 2025 after selling out during the quarter.
  • Charles Schwab sold 1,003,074 89bio shares in Q4 2025, an estimated $14.7M.
  • Charles Schwab first reported a position in 89bio in Q4 2019 and held it in 23 quarters.
  • Charles Schwab's 89bio position peaked at $14.7M in Q3 2025.
  • 2 funds tracked by Wall St. Rank held 89bio as of Q4 2025.

Based on Charles Schwab's 13F filing for Q4 2025, filed 13 Feb 2026.